ly4178256

ly4178256: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Lead developer: ELI LILLY & Co (LLY)

Get the AI investment thesis on ly4178256

Development Pipeline (1)

Clinical Trials (1)

A Phase 1, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4178256 in Healthy Participants

NCT07698210·Phase 1·LLY
Not yet recruiting

Frequently asked questions

Who is developing ly4178256?

ly4178256 is being developed by ELI LILLY & Co.

How many clinical trials involve ly4178256?

BioSniper tracks 1 clinical trial involving ly4178256.

Analyze ELI LILLY & Co & ly4178256 with AI

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start AI Analysis
    ly4178256 — Drug Pipeline, Trials & FDA Status | BioSniper